Japan, Sept. 16 -- GENENTECH INC has got intellectual property rights for 'CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES.' Other related details are as follows:
Application Number: JP,2020-209885
Category (FI): A61K39/395@D,C12N15/13,C12P21/08,A61K31/403,A61K31/5517,A61K38/07,A61K39/395@N,A61P37/06,A61P29/00,A61P25/00,A61P35/02,A61P35/00,A61K45/00,A61K47/68,C07K16/28
Stage: PROBLEM TO BE SOLVED: To provide novel cysteine engineered antibodies comprising a free cysteine amino acid in a heavy chain or light chain and to provide conjugates.SOLUTION: A cysteine engineered antibody comprising a free cysteine amino acid in a heavy chain or light chain is prepared by: mutagenizing a nucleic acid sequence of a parent antibody so as to encode the cysteine engineered antibody; replacing one or more amino acid residues by cysteine; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody.SELECTED DRAWING: None (Grant)
Filing Date: Dec. 18, 2020
Publication Date: May 13, 2021
The original document can be viewed at: https://www.j-platpat.inpit.go.jp/p0100
Disclaimer: Curated by HT Syndication.
